23andMe Investor Presentation Deck slide image

23andMe Investor Presentation Deck

Our Scale Enables Real-Time Research Across Multiple Disease Areas Including (numbers below represent the number of research participants with the condition indicated) Example Phenotype Asthma Type 1/ Type 2 diabetes Irritable Bowel Syndrome Osteoarthritis Solid Tumors Basal Cell Squamous Cell Melanoma Breast Colorectal Thyroid Hematologic Cancers NHL Leukemia Retinal Diseases AMD Glaucoma Rare Diseases Sarcoidosis Idiopathic Pulmonary Fibrosis Number of Cases¹ 1.2M 40K / 413k 742k 857k > 1M 412k 222k 127k 119k 25k 27k 18k 14k 106k 193k 8.9k 5k ¹ As of December, 2022. 2 MedRXiv Sept. 7, 2020 (10.1101/2020.09.04.20188318). 3 Nature Genetics, 53, pages 801-808 (2021) > 1.4M COVID-19 study participants COVID-19 Research March 16 2020 April 6 2020 June 8 2020 Sept. 7 2020 750k Consumers participated in the COVID-19 study in the first 90 days April 22 2021 Kicked Off Study Launched Study Preliminary Findings Posted Preprint Findings² Published in Journal³ Re-contactable Customers Participate in Health Research 29
View entire presentation